Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.

Thomas El Jammal, Mathieu Gerfaud-Valentin, Pascal Sève, Yvan Jamilloux

Joint bone spine 2020 Mar

filter terms:

Three Janus kinase (JAK) inhibitors, ruxolitinib, tofacitinib, and baricitinib, are currently approved by the FDA/EMA for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative rectocolitis. The inhibition of JAK/STAT signaling by these small molecules, downstream of several cytokine receptors, results in lower pro-inflammatory gene expression. Given the cytokine profiles observed in rheumatologic diseases, most of the recent therapeutic strategies target cytokines, either directly or through their receptors. Each cytokine receptor recruits a specific combination of JAKs to activate different programs in cells. The approved drugs are panJAK inhibitors, able to impede more than one pathway. These drugs are being tested in various rheumatologic disorders. At the same time, more specific molecules able to target one specific JAK are being developed. In this review, we describe the expanding spectrum of rheumatologic and autoimmune conditions for which JAK inhibition may represent new avenues in clinical practice. Copyright © 2019 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.

Citation

Thomas El Jammal, Mathieu Gerfaud-Valentin, Pascal Sève, Yvan Jamilloux. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum. Joint bone spine. 2020 Mar;87(2):119-129